Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages

  Thiboutot, Diane ^a   Arsonnaud, Stephanie ^b   Soto, Pascale ^b   Johnson, Lori A ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Galderma R and D   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE; NICOTINIC ACID DERIVATIVE; TAZAROTENE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; GEL; HUMAN; MALE; MULTICENTER STUDY; PATHOLOGY; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; GELS; HUMANS; MALE; NAPHTHALENES; NICOTINIC ACIDS; QUESTIONNAIRES; SKIN;

EID: 52449123773     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1:1109-1110. (Pubitemid 9153234)
2. Usatine RP, Quan MA, Strick R. Acne vulgaris: a treatment update. Hosp Pract (Minneap). 1998;33:111-117,121-114,127.
3. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol. 1995;32:S15-S25.
4. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004;14:4-12. (Pubitemid 38187090)
5. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49 (suppl):S1-S37. (Pubitemid 36791495)
6. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651-663. (Pubitemid 46400177)
7. Jones DA. The potential immunomodulatory effects of topical retinoids. Dermatol Online J. 2005;11:3.
8. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196:119-125. (Pubitemid 28116058)
9. Brogden RN, Goa KE. Adapalene. a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997;53:511-519. (Pubitemid 27117366)
10. Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol. 1998;139 (suppl):3-7. (Pubitemid 28475276)
11. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36:S126-S134. (Pubitemid 27265894)
12. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996;34:482-485. (Pubitemid 26083828)
13. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139 (suppl):26-33.
14. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68 (suppl):10-19.
15. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials. Br J Dermatol. 1998;139 (suppl):48-56.
16. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49 (suppl):S211-S217. (Pubitemid 37046535)
17. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? a comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003;49 (suppl):S218-S226. (Pubitemid 37046536)
18. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69 (suppl):4-11.
19. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63:349-354.
20. Hensby C, Cavey D, Bouclier M, et al. The in vivo and in vitro anti-inflammatory activity of cd271: A new retinoid-like modulator of cell differentiation. Agents Actions. 1990;29:56-58. (Pubitemid 20091843)
21. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis. 2001;67 (suppl):10-16.
22. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67 (suppl):4-9.